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Available online xxxxThis retrospectivemulticenter study in patients with chronicmyeloid leukemia in chronic phasewas undertaken
to conﬁrm the clinical relevance of imatinib plasma concentrations monitoring in daily practice. Forty-one pa-
tients, with 47 imatinib plasma measurements, were analyzed during treatment with imatinib given at a ﬁxed
400mg daily dose. A signiﬁcant inverse relationship of imatinib concentration with the patients' weight was ob-
served (Pearson's test: p=0.02, R2= 0.1). More interestingly, patients with poor response (switched to another
tyrosine kinase inhibitor because of imatinib failure, or because of disease progression after an initial response)
displayed a signiﬁcantly lower mean imatinib concentration as compared to patients maintained on imatinib
(822 ng/mL vs 1099 ng/mL; Student's t-test, p=0.04). Failure or disease progression occurredmore often in pa-
tients in the lowest quartile of imatinib concentrations compared to patients in the highest quartile (p = 0.02,
logrank test). No correlation could be established with other biological or clinical parameter, including complete
cytogenic response andmajormolecular response. In conclusion: in patients treatedwith imatinib at a ﬁxed daily
dose of 400 mg, imatinib plasma concentrations decreased with increasing body weight and were lower in pa-
tients switched to another tyrosine kinase inhibitor due to imatinib failure. Systematic determination of imatinib
plasma trough levels should be encouraged in such patients.
© 2016 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.Keywords:
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The course of chronic myeloid leukemia (CML) has dramatically im-
proved since imatinib mesylate (IM), the ﬁrst member of a family of ty-
rosine kinase inhibitors (TKI) with BCR-ABL1 blocking activity, wasent of Hematology, rue Ferrer,
oy).
in.
ists. Published by Elsevier Inc. All rig
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x.doi.org/10.1016/j.clinbiochemade available for clinical use [1]. In contrast with most anti-cancer
drugs, IM and next generation TKIs are administered at ﬁxed dose
(most often 400mg of IM daily during the chronic phase of the disease)
irrespective of the patient's physical characteristics, including weight,
body surface and body mass index (BMI). Yet, a wide variation of plas-
ma trough IM concentration was repeatedly demonstrated in such pa-
tients according to weight, interaction with concomitant drugs,
malabsorption, renal and hepatic functions, genetic factors and, last
but not least, as a function of patient compliance with treatment [2].
IM concentration correlates with cytogenetic and molecular responsehts reserved.
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2 F. Van Obbergh et al. / Clinical Biochemistry xxx (2016) xxx–xxxto treatment, which, in turn, correlates with clinical outcome [3]. Picard
et al. determined that the ideal trough IM plasma concentration should
be at least 1000 ng/mL [4].
Since 2009, IM plasma concentration assessment was made avail-
able to Belgian hematologists on a voluntary basis. Meanwhile, second
generation TKIs became available in Belgium for patients with intoler-
ance or after failure of IM. Change of treatment to the newTKIs after fail-
ure of IM provided us with a new operational deﬁnition of IM failure. In
this work, we analyzed the clinical relevance of IM therapeutic drug
monitoring in patients with CML in the chronic phase including an anal-
ysis of the relationship between IM trough concentrations and treat-
ment failure, deﬁned by a change of TKI for resistant or relapsing
disease.Fig. 1. Relationship betweenweight and plasma IM concentration. The inverse correlation
between weight and IM plasma concentrations is signiﬁcant (p= 0.02, Pearson's test).2. Patients and methods
This is a retrospectivemulticenter studyperformed in Belgianhema-
tology departments who volunteered to communicate clinical data on
patients with CML treated with IM, and with at least one IM plasma
(EDTA) concentration assessment. IM concentrations presented here
were determined by a liquid chromatographic tandem mass-spectro-
metric method (LC-MSMS) in the laboratories of UCL St Luc University
Hospital, Brussels, as described elsewhere [5], and of theUniversity Hos-
pital, Leuven (UZ Leuven). Only patientswith chronicmyeloid leukemia
in chronic phase treated with IM 400 mg daily were analyzed after
obtaining the ethics committee approval in hospitals requesting such
an approval for retrospective studies. This study was carried out in ac-
cordance with The Code of Ethics of the World Medical Association
(Declaration of Helsinki) for experiments involving humans. Cytogenet-
ic responsewas complete if no Ph1 chromosomewas observed after an-
alyzing at least 20 metaphases, while a major molecular response was
deﬁned by a BCR-ABL1 expression ≤0.1%, according to the European
Leukemia Net recommendations [6].
Continuous data were correlatedwith the use of Pearson's test while
categorical data were compared by Student's t-test after checking that
data distribution was normal. Means are reported ±2 Standard errors
when appropriate. Failure or progression probability curves over time
(deﬁned by a change of TKI unrelated to intolerance to IM) were calcu-
lated according to Kaplan and Meier's estimate of survival method and
were compared by the logrank test [7,8].Table 1




Age (years) 41 49 17–87
Sex: Male/female 23/18
Weight (kg) 39 76 49–140
Height (cm) 31 169 148–200
Body surface area (m2) 31 1.89 1.43–2.79
BMI (Kg/m2) 31 26.2 18.4–35
IM concentration (ng/mL) 47 938 287–2013
Creatinine (mg/dL) 41 0.9 0.5–1.6
Time interval between diagnosis and ﬁrst IM
plasma concentration (years)
40 2.2 0.15–12.3
Sokal score at diagnosis: low-intermediate-high 18-12-3
Hasford score at diagnosis:
low-intermediate-high
17-10-1
Eutos score at diagnosis: low-high 16-2
Follow-up duration (years) 40 6.1 0.53–15.1
Cytogenetic response: complete-partial-failure 31-5-1
Molecular response: major or complete-less than
major
28-11
Change of TKI: no-yes for failure-yes for toxicity 24-13-4
Disease acceleration 2
Transformation to acute leukemia 0
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Forty-one patients involving 47 IM plasma concentrations were an-
alyzed. The main clinical data at IM concentration measurement, re-
sponse to therapy, and outcome are summarized in Table 1. During
follow-up (median duration: 6.1 years) CML acceleration was observed
in 2 cases. Thirteen patients had to change to another TKI because of
molecular resistance or progression on IM. In addition, 4 patients were
switched to nilotinib or dasatinib because of intolerance to IM.
Correlations studies showed a signiﬁcant inverse relationship of IM
concentration with weight (p = 0.02), as shown in Fig. 1, and with
height (p = 0.02). Body surface, mass index and age did not correlate
with IM concentrations.
Categorical data analysis showed a lower mean IM concentration
(822 ng/mL ± 200) in patients who later changed to another TKI be-
cause of poormolecular response (8 patients) or molecular disease pro-
gression (5 patients) compared to patients whoweremaintained on IM
(24 patients) or who changed to another TKI because of intolerance to
IM (4 patients) (mean IM concentration 1099 ± 156 ng/mL, p = 0.04,
Student's t-test). Cytogenetic and molecular response did not correlate
with IM concentrations.
Finally, we tried to conﬁrm the link between IM concentrations and
CML progression by assessing the progression-free survival in the four
quartiles of patients deﬁned on the basis of IM concentrations, from
the ﬁrst quartile (Q1) with the lowest IM concentrations, to the fourth
quartile (Q4) with the highest IM concentrations (Fig. 2). Progression
probability over time in patients in the lower IM quartile (Q1) was sta-
tistically higher by the logrank test when compared to progression riskFig. 2. Progression or failure probability, according to plasma IM concentrations in the 41
patients. Failure or progressionwas deﬁned as a change of TKI not related to intolerance to
IM. Q1, Q2, Q3, and Q4 represent patients belonging to the ﬁrst, second, third, and fourth
quartile of IM concentrations, respectively, from the lowest to the highest IM
concentrations. Time was calculated from diagnosis. Differences between Q1 and Q2 and
between Q1 and Q4 are statistically signiﬁcant (logrank test, p= 0.02).
atinib plasma trough concentrations in chronic myeloid leukemia. A
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sion difference could be established between patients in Q1 and Q3
(p= 0.1).
4. Discussion
This retrospective multicenter study conﬁrms the inverse relation-
ship between body weight/height and IM trough plasma concentra-
tions, and does not support the use of ﬁxed IM doses. In our study, no
correlation with cytogenic failure could be demonstrated, probably be-
cause failures to achieve a complete cytogenic response were rare (6/
37); molecular response failed to correlate with IM concentrations but
molecular studies were not centralized in this retrospective study and
thus proved difﬁcult to compare. However, our data show that a low
IMplasma trough concentration is associatedwith treatment failure de-
ﬁned as a change of TKI after failure of IM or after progression following
a major response. In addition, a recent randomized study reported by
Rousselot et al. strongly suggests that adapting IM dose in order to
reach therapeutic plasma concentrations has a favorable impact on the
treatment response, which strengthens our recommendation to per-
form IM therapeutic drug monitoring in CML patients [9]. This recom-
mendation is particularly important in patients with risk factors for
low IM concentrations (obesity, malabsorption, multiple medica-
tions…) but should be expanded to all patients as inappropriately low
IM concentrations can be observed in patients with no risk factor and
as poor compliance to treatment (approximately 30% of patients) can
be suspected on the basis of unusually low concentrations or of hectic
results [10].
This research did not receive any speciﬁc grant from funding agen-
cies in the public, commercial, or not-for-proﬁt sectors.
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